Orexo (ORX.ST) Stock Analysis & AI Equity Report
Orexo (ORX.ST) overview
Orexo (ORX.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Orexo reported revenue of SEK 26.0m and operating profit of SEK -347m; the year-end share price was 30.10 SEK and market capitalisation was SEK 1,042m. Orexo is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Orexo's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Orexo
Orexo AB is a Swedish pharmaceutical company focused on developing and commercializing treatments for severe diseases and life-saving rescue medicines. Its core platform, AmorphOX, is a drug delivery technology designed to improve bioavailability and stability across large and small molecules. The company also has a diversified pipeline of clinical and preclinical programs and collaborates with partners on development and commercialization.
Generate the Orexo report
Orexo is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Orexo and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.